ResMed is redoubling efforts to increase resupply with plans to make Snap, a software platform that monitors orders, ...

A stellar first quarter has underscored ResMed's share price bounce-back from last year's obesity drug panic, and perhaps put ...

There's plenty more upside, this fund says. The post Why this fundie is backing ResMed shares in FY25 appeared first on The ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

The market feared that would reduce demand for ResMed’s various CPAP airflow machines, which patients wear during sleep to ...

Med’s leadership position in sleep apnea has combines its digital health ecosystem and new hardware to pair with smart watches and wearables that creates an end-to-end solution for diagnosis of sleep ...

Many analysts see GLP-1 drugs, which have shown positive results in treating sleep apnea, as a threat to CPAP companies. But ResMed, which makes sleep apnea devices, sees an opportunity.

ResMed (RMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 millionNote: A webcast of ...

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post ...

Hello, and welcome to the Q1 fiscal year 2025 ResMed Earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note this conference call is ...